knowledge -WSS

knowledge

author：focus 2025-09-27 23:33:11 - browse：6525

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Millions may soon lose Medicaid when they don't have to

hotspot

WSS

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Xenotransplantation trials will require adjusting expectations, experts say

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

The EU Joint Clinical Assessment needs to live up to its promise

The EU Joint Clinical Assessment needs to live up to its promise

Senate committee scrutinizes Medicare Advantage brokers

focus

knowledge

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Will Ozempic

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA struggles to regulate food additives, sometimes for decades

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Readout Newsletter: Today's biggest biotech updates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HHS leader on health, climate change and biopharma emissions

Anesthesiologist group: stop taking Ozempic before surgery

Millions may soon lose Medicaid when they don't have to

hotspot

Beam Therapeutics to lay off 20% of its staff, re

Solve the antibiotic resistance crisis with preventive drugs

Millions may soon lose Medicaid when they don't have to

Senate panel passes drug pricing bills, but drops one PBM reform

How to fix the rural physician shortage in the U.S.

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

hotspot

focus

entertainment